Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
A Randomised, Double-blind, Parallel Group, 12 Week Study, Comparing the Effect of Once Daily Tiotropium Lactose Capsule With Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD), naïve to Anticholinergic Agents in Addition to Receiving Their Usual COPD Care
Verified date | October 2013 |
Source | Boehringer Ingelheim |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Medicines Control Agency |
Study type | Interventional |
The objective of the study is to determine the effect on lung function when either SPIRIVA
once daily or placebo once daily is added to the usual therapy (care) of COPD patients naïve
to anticholinergic agents managed in primary care. Previous studies have been in both
hospital in and outpatients, with washout of some respiratory medications, this is the first
study to be conducted in General Practice, the drug's anticipated environment.
Data from this study, including the adverse event monitoring, and post study findings on
physical examination, will be used to extend the safety database. Health Resource
Utilisation (HRU) data will be recorded to be use with data from other sources for economic
analysis of COPD treatment.
Status | Completed |
Enrollment | 395 |
Est. completion date | October 2003 |
Est. primary completion date | October 2003 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Prior to participation in the study all patients must sign and date an informed consent consistent with ICH-GCP guidelines. - Male or female patients 40 years of age or older. - Patients with a diagnosis of COPD according to BTS criteria..A stable disease state with airway obstruction of FEV1 between 30- 65% of predicted normal value and FEV1 /FVC<70% pre bronchodilators. - Predicted normal values will be calculated according to ECCS: - For height measured in metres - Males: FEV1 predicted (L) = 4.30 X (Ht in mts) - 0.029 X (Age in yrs) - 2.49 - Females:FEV1 predicted (L) = 3.95 X (Ht in mts) - 0.025 X (Age in yrs) - 2.60 - For height measured in inches - Males: FEV1 predicted (L) = 4.30 X (Ht in inches/39.37) - 0.029 X (Age in yrs) - 2.49 - Females:FEV1 predicted (L) = 3.95 X (Ht in inches/39.37) - 0.025 X (Age in yrs) - 2.60 - Maintained on a stable respiratory medication for 4 weeks prior to visit 1 (no changes in respiratory medication oral dosage). - Currently taking salbutamol or terbutaline MDI or DPI. - Patient must be able to inhale medication through the HandiHaler? - Patients must be able to perform technically acceptable pulmonary function tests in accordance with ATS criteria and must be able to maintain records (Patient Daily Record) during the study period as required in the protocol. - Patients must be current or ex-smokers with a smoking history of more than 10 pack years. - Pack Years = Number of cigarettes/day 20 (Patients who have never smoked cigarettes must be excluded.) NOTE: An exacerbation of COPD requiring treatment occurring within the four week period prior to screening visit 1 will mean that screening should be postponed for at least four weeks. Therefore, the patient should have duration of at least 4 weeks free of exacerbations. Exclusion Criteria: - Patients with significant diseases, other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study. - Patients who have taken inhaled anticholinergics in the previous 12 months. Patients that have been treated with inhaled anticholinergics (via nebuliser or metered dose inhaler) due to an exacerbation for a time period no longer than 7 days may be included. - Patients with an upper respiratory tract infection or exacerbation of COPD requiring treatment in the four weeks prior to the screening visit (visit 1) or during the two-week run-in period. Patients with a recent history (i.e., six months or less) of myocardial infarction. - Any unstable or life threatening cardiac arrhythmia requiring intervention or a change in drug therapy within the last year. - Patients with known active tuberculosis. - Patients who have a history of thoracotomy with pulmonary resection or have planned lung transplantation or lung volume reduction surgery. - Patients with a history of asthma, cystic fibrosis, bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease. - Patients who are being treated with antihistamines (H1 receptor antagonists) for asthma or excluded allergic conditions. - Patients with a history of cancer in the last five years; Basal cell tumours or patients whose length of time in remission is greater than five years can be included. - Patient with known hypersensitivity to atropine, and other anticholinergic drugs or lactose or any previous adverse reaction to anticholinergic drugs that resulted in withdrawal of the anticholinergic compound. - Patients using oral corticosteroid medication at unstable doses (i.e. Patients have been on a stable dose for less than 6 weeks prior to randomisation) or at doses in excess of the equivalent of 10mg o |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Foresterhill Healthcentre | Aberdeen | |
United Kingdom | Boehringer Ingelheim Investigational Site | Airdrie | |
United Kingdom | Boehringer Ingelheim Investigational Site | Atherstone | |
United Kingdom | Boehringer Ingelheim Investigational Site | Barry | |
United Kingdom | Boehringer Ingelheim Investigational Site | Bath | |
United Kingdom | Boehringer Ingelheim Investigational Site | Bath | |
United Kingdom | The Beehive Surgery, Bath | Bath | |
United Kingdom | Boehringer Ingelheim Investigational Site | Bedworth | |
United Kingdom | Boehringer Ingelheim Investigational Site | Bellshill | |
United Kingdom | Boehringer Ingelheim Investigational Site | Bexhill | |
United Kingdom | Boehringer Ingelheim Investigational Site | Bexhill-on-Sea | |
United Kingdom | Health Centre | Biggar | |
United Kingdom | Bradford Health Centre | Bradford Upon Avon | |
United Kingdom | Pembroke Road Surgery | Bristol | |
United Kingdom | Boehringer Ingelheim Investigational Site | Cardiff | |
United Kingdom | Boehringer Ingelheim Investigational Site | Chapelhall | |
United Kingdom | Boehringer Ingelheim Investigational Site | Coatbridge | |
United Kingdom | Coatbridge Health Centre | Coatbridge | |
United Kingdom | Boehringer Ingelheim Investigational Site | Corsham | |
United Kingdom | Boehringer Ingelheim Investigational Site | Corsham | |
United Kingdom | Boehringer Ingelheim Investigational Site | Coventry | |
United Kingdom | Boehringer Ingelheim Investigational Site | Doncaster | |
United Kingdom | Boehringer Ingelheim Investigational Site | Garston | |
United Kingdom | Boehringer Ingelheim Investigational Site | Glasgow | |
United Kingdom | Boehringer Ingelheim Investigational Site | Glasgow | |
United Kingdom | Boehringer Ingelheim Investigational Site | Glasgow | |
United Kingdom | Boehringer Ingelheim Investigational Site | Glasgow | |
United Kingdom | Boehringer Ingelheim Investigational Site | Glenboig | |
United Kingdom | Princess Street Surgery | Gorseinon | |
United Kingdom | Boehringer Ingelheim Investigational Site | Hamilton | |
United Kingdom | Boehringer Ingelheim Investigational Site | Haverfordwest | |
United Kingdom | Boehringer Ingelheim Investigational Site | Heywood | |
United Kingdom | Boehringer Ingelheim Investigational Site | Holt | |
United Kingdom | Boehringer Ingelheim Investigational Site | Kingswood | |
United Kingdom | Boehringer Ingelheim Investigational Site | Leamington Spa | |
United Kingdom | Boehringer Ingelheim Investigational Site | Leicester | |
United Kingdom | Boehringer Ingelheim Investigational Site | Melksham | |
United Kingdom | Boehringer Ingelheim Investigational Site | Plymouth | |
United Kingdom | St Chads Surgery | Radstock | |
United Kingdom | Boehringer Ingelheim Investigational Site | Rutherglen | |
United Kingdom | Boehringer Ingelheim Investigational Site | Sheffield | |
United Kingdom | Boehringer Ingelheim Investigational Site | Soham | |
United Kingdom | Boehringer Ingelheim Investigational Site | Wishaw | |
United Kingdom | Boehringer Ingelheim Investigational Site | Woking |
Lead Sponsor | Collaborator |
---|---|
Boehringer Ingelheim |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Trough Forced Expiratory Volume in one second (FEV1) response determined at the end of the 12- week treatment period | week 12 | No | |
Secondary | Trough FEV1 response after 2 and 6 weeks | week 2, week 6 | No | |
Secondary | Trough Forced Vital Capacity (FVC) response after 2, 6 and 12 weeks | week 2, week 6, week 12 | No | |
Secondary | Dyspnoea measured by the Oxygen Cost Diagram (OCD | week 12 | No | |
Secondary | Weekly mean number per day of occasions when Short Acting ß2 Agonist (SABA) therapy was used | week 12 | No | |
Secondary | Percentage compliance with study medication as assessed by inhalation capsule counts | week 12 | No | |
Secondary | Adverse events | week 12 | No | |
Secondary | Seated pulse rate and blood pressure | week 12 | No | |
Secondary | Physical examination | week 12 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|